Valuation: Curatis Holding AG

Market Cap 102M 123M 108M 92.73M 174M 11.77B 175M 1.22B 472M 6.01B 461M 451M 19.32B P/E 2024
-8.71x
P/E 2025 -42.3x
Enterprise Value 99.89M 121M 106M 91.03M 170M 11.55B 172M 1.2B 463M 5.9B 453M 443M 18.97B EV / Sales 2024
8,696,370x
EV / Sales 2025 5,424,304x
Free-Float
22.09%
Yield 2024 *
-
Yield 2025 -
1 day+6.88%
1 week+6.88%
Current month+6.32%
1 month+1.51%
3 months-8.60%
6 months-10.22%
Current year+68.33%
1 week 18.4
Extreme 18.4
20.8
1 month 17.45
Extreme 17.45
20.9
Current year 11.75
Extreme 11.75
27.9
1 year 11.05
Extreme 11.05
27.9
3 years 5
Extreme 5
27.9
5 years 5
Extreme 5
27.9
10 years 5
Extreme 5
27.9
Date Insider Type Main position Quantity % Market Cap. Importance
5/27/26 Sell -9,664 0.1874%
4/8/26 Sell 4,000 0.0776%
1/13/26 Sell 209 0.0041%
Change 5-day change 1-year change 3-year change Capi.($)
+6.88%+6.88%+52.45% - 121M
-1.00%-0.18%+36.58%-4.46% 79.49B
+2.08%+25.82%+668.47%+98.90% 77.78B
-1.21%-0.34%-10.33%-29.82% 60.16B
-1.80%-2.15%-15.06%+26.38% 46.14B
+1.18%+2.78%+4.84%+161.08% 45.93B
+0.55%+3.90%+65.32%-11.67% 33.45B
-0.44%-2.92%+47.21%+113.24% 25.22B
-0.10%+3.69%+4.89%+166.22% 22.15B
+0.05%-2.15%+57.47%+98.45% 15.25B
Average +0.37%+3.07%+91.18%+68.70% 40.57B
Weighted average by Cap. -0.51%+4.93%+143.39%+53.77%

Financials

2024 2025
Net sales 6.9 8.32 7.3 6.28 11.76 797.51 11.85 82.52 31.96 407.43 31.24 30.57 1.31K 10.8 13.03 11.44 9.84 18.42 1.25K 18.56 129.24 50.06 638.09 48.93 47.87 2.05K
Net income -4.34M -5.24M -4.6M -3.96M -7.41M -502M -7.47M -51.99M -20.14M -257M -19.68M -19.26M -825M -1.42M -1.71M -1.5M -1.29M -2.42M -164M -2.43M -16.94M -6.56M -83.66M -6.42M -6.28M -269M
Net Debt -3.01M -3.64M -3.19M -2.75M -5.14M -349M -5.18M -36.07M -13.97M -178M -13.65M -13.36M -572M -1.87M -2.25M -1.98M -1.7M -3.18M -216M -3.21M -22.34M -8.65M -110M -8.46M -8.28M -355M
Logo Curatis Holding AG
Curatis Holding AG formerly Kinarus Therapeutics Holding AG is a Switzerland-based company that operates in specialty pharmaceutical and therapeutic drug industry. The Company conducts its work within clinical-stage area and focuses on the acquisition, development and commercialisation of medicines for the prevention, diagnosis and treatment of diseases. This is done by distributing specialty pharmaceuticals throughout Switzerland, with aims to expanded to larger European markets such as Germany, France, United Kingdom as well as Italy. The drugs and treatments produced are primarily developed in order to treat rare diseases, often referred to as orphan diseases, which receive little funding, relative to more common disorders.
Employees
9
Date Price Change Volume
26-09-25 CHF 19.15 +1.32% 797
26-09-24 CHF 18.90 -0.53% 134
26-09-23 CHF 19.00 -0.78% 1,991
26-09-22 CHF 19.15 +3.51% 1,135
26-09-21 CHF 18.50 -8.42% 6,359
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
CCC

Annual profits - Rate of surprise

  1. Stock Market
  2. Stocks
  3. CURN Stock